FBLG vs. LYEL, HURA, ZNTL, NLTX, CRGX, VXRT, ACRV, CDTX, ALEC, and ACRS
Should you be buying FibroBiologics stock or one of its competitors? The main competitors of FibroBiologics include Lyell Immunopharma (LYEL), TuHURA Biosciences (HURA), Zentalis Pharmaceuticals (ZNTL), Neoleukin Therapeutics (NLTX), CARGO Therapeutics (CRGX), Vaxart (VXRT), Acrivon Therapeutics (ACRV), Cidara Therapeutics (CDTX), Alector (ALEC), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry.
FibroBiologics vs.
FibroBiologics (NASDAQ:FBLG) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation, community ranking and profitability.
66.1% of Lyell Immunopharma shares are held by institutional investors. 20.8% of FibroBiologics shares are held by insiders. Comparatively, 25.1% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Lyell Immunopharma received 5 more outperform votes than FibroBiologics when rated by MarketBeat users. However, 100.00% of users gave FibroBiologics an outperform vote while only 48.28% of users gave Lyell Immunopharma an outperform vote.
In the previous week, Lyell Immunopharma had 1 more articles in the media than FibroBiologics. MarketBeat recorded 2 mentions for Lyell Immunopharma and 1 mentions for FibroBiologics. FibroBiologics' average media sentiment score of 0.00 equaled Lyell Immunopharma'saverage media sentiment score.
FibroBiologics presently has a consensus target price of $13.00, indicating a potential upside of 1,055.56%. Lyell Immunopharma has a consensus target price of $1.00, indicating a potential upside of 42.71%. Given FibroBiologics' stronger consensus rating and higher probable upside, equities research analysts clearly believe FibroBiologics is more favorable than Lyell Immunopharma.
FibroBiologics has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -323,792.09%. FibroBiologics' return on equity of 0.00% beat Lyell Immunopharma's return on equity.
FibroBiologics has higher earnings, but lower revenue than Lyell Immunopharma.
Summary
FibroBiologics beats Lyell Immunopharma on 8 of the 14 factors compared between the two stocks.
Get FibroBiologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
FibroBiologics Competitors List
Related Companies and Tools
This page (NASDAQ:FBLG) was last updated on 2/22/2025 by MarketBeat.com Staff
